LXEO
Lexeo Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$4.54-3.20%
Price as of Jul 20, 2026
LXEO ownership
Lexeo Therapeutics, Inc. Common Stock ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
6
Net (3m)
-$280.1K
Insider trades by month Buys Sells
Oct
Nov
Feb
Apr
May
Jul
Context3-month price -15.6%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 1, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 25,947 | $4.48 |
| Jul 1, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 12,000 | — |
| Jul 1, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Sell | 4,641 | $4.49 |
| Jul 1, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 12,060 | — |
| Jul 1, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 4,666 | $4.48 |
| Jul 1, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 55,000 | — |
| Jul 1, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Sell | 22,306 | $4.42 |
| Jul 1, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 67,000 | — |
| Jun 29, 2026 | Altschuler Stevendirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | Agger Mette Kirstinedirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | COOPERSTONE BRENDAdirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | DIAZ REINALDO Mdirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | Tanguler Tolgadirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | Van Hauwermeiren Timothydirector | Grant | 35,000 | $4.70 |
| Jun 29, 2026 | CHOLMONDELEY PAULA Hdirector | Grant | 35,000 | $4.70 |
| May 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 1,302 | $5.07 |
| May 20, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 3,342 | $5.06 |
| Apr 30, 2026 | Sepp-Lorenzino Lauradirector | Grant | 50,000 | $5.81 |
| Apr 7, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 55,000 | $5.69 |
| Mar 17, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 5,930 | $2.64 |
| Mar 17, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 2,623 | $2.64 |
| Feb 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 721 | $9.27 |
| Feb 20, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Sell | 10,173 | $6.38 |
| Feb 20, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Sell | 3,016 | $6.40 |
| Feb 17, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 49,500 | — |
| Feb 17, 2026 | Bhalla Narinder Palofficer: Chief Medical Officer | Grant | 297,000 | $6.31 |
| Feb 6, 2026 | Townsend Richard Nolandirector, officer: Chief Executive Officer | Grant | 646,665 | $7.27 |
| Feb 6, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 44,665 | — |
| Feb 6, 2026 | Tamayo Louis Edwardofficer: Chief Financial Officer | Grant | 226,665 | $7.27 |
| Feb 6, 2026 | Otero Jose Manuelofficer: Chief Operating Officer | Grant | 65,000 | — |
Source: LXEO SEC Form 4 filings, latest Jul 1, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their LXEO positions over the last 6 months (SEC Form 13F).
Increased
119
New positions
62
Reduced
68
Sold out
42
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| PARADIGM BIOCAPITAL ADVISORS LP | Increased | 6.2M | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 5.5M | Feb 17, 2026 |
| BLACKROCK, INC. | Increased | 5.1M | May 13, 2026 |
| AFFINITY ASSET ADVISORS, LLC | Increased | 5.1M | May 14, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | New Position | 5.0M | Feb 17, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 5.0M | May 15, 2026 |
| JANUS HENDERSON GROUP PLC | Reduced | 5.0M | May 18, 2026 |
| BLACKROCK, INC. | Increased | 4.9M | Feb 12, 2026 |
| PARADIGM BIOCAPITAL ADVISORS LP | New Position | 4.8M | Feb 17, 2026 |
| VESTAL POINT CAPITAL, LP | Increased | 4.5M | Feb 17, 2026 |
| VESTAL POINT CAPITAL, LP | Unchanged | 4.5M | May 15, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4.4M | Feb 13, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 4.4M | May 15, 2026 |
| VANGUARD GROUP INC | Increased | 3.9M | Jan 29, 2026 |
| CITADEL ADVISORS LLC | Increased | 3.8M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.